Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease
Customize your policy alerts
Sign up for univerahealthcare Policy 2.02.19 alerts
Get alerted when Policy 2.02.19 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of serologic biomarker testing used to evaluate inflammatory bowel disease, including testing intended to diagnose or monitor IBD or distinguish ulcerative colitis from Crohn's disease. The policy applies to providers requesting these laboratory services for members.
The policy underwent an annual review on November 19, 2026, with policy intent unchanged.
Coverage Criteria
Serum antibody testing for IBD
Serologic testing of biomarkers for inflammatory bowel disease (IBD) is considered not medically necessary for all indications, including but not limited to the following tests and uses.
The following apply
Serologic biomarkers include, but are not limited to
- Anti-neutrophil cytoplasmic antibodies (ANCA) or anti-Saccharomyces cerevisiae (ASCA).
- Antibodies to outer membrane porin C of the bacteria Escherichia coli (anti-OmpC).
- Pseudomonas fluorescens-associated sequence I2 (anti-I2).
- Flagellin CBir1 (anti-CBir1).
- Antichitobioside antibodies (ACCA IgA).
- Antilaminaribioside antibodies (ALCA IgG).
- Antimannobioside antibodies (AMCA IgG).
Testing indications include, but are not limited to
- Diagnosing and monitoring patients with inflammatory bowel disease (IBD).
- Distinguishing ulcerative colitis (UC) from Crohn's disease (CD).
Serologic testing of biomarkers, including Prometheus IBD sgi Diagnostic testing, is considered not medically necessary for all indications. This determination includes testing intended to diagnose or monitor IBD or to distinguish ulcerative colitis from Crohn's disease, and is not limited to the specific biomarkers listed above.
Coding Information
| 81479 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| 82397 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| 83516 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| 83520 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| 86140 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| 88346 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| 88350 | May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD. |
| No codes listed |
| K50.00-K50.919 | Crohn's disease [regional enteritis] (code range) |
| K51.00-K51.919 | Ulcerative colitis (code range) |
Provider Guidance
Serologic IBD biomarker testing is not medically necessary
Do not request serologic IBD biomarker testing, including PROMETHEUS IBD sgi Diagnostic testing or antibody panels, because it is considered not medically necessary for all indications. This includes testing to diagnose or monitor inflammatory bowel disease or to distinguish ulcerative colitis from Crohn’s disease.
Unsupported diagnostic or prognostic serology
Do not use serologic antibody testing to establish or rule out ulcerative colitis, establish a diagnosis of Crohn’s disease, or determine ulcerative colitis prognosis. The American College of Gastroenterology does not support these uses.
- Routine use of serologic markers of IBD to establish the diagnosis of Crohn’s disease is not indicated.
- Serologic antibody testing is not recommended to establish or rule out ulcerative colitis or determine its prognosis.
Clinical Background
Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis. Their clinical presentations may overlap, and approximately 10–15% of patients cannot be definitively classified as having either condition and are diagnosed with indeterminate colitis. Endoscopic examination and biopsy remain important components of diagnosis.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.